GC Green Cross Publishes Research on Next-Generation Hemophilia Treatment in International Journal

[Asia Economy Reporter Jihee Kim] GC Green Cross announced on the 20th that the research results on the next-generation hemophilia antibody therapeutic 'MG1113' were published in the SCI-level international journal Thrombosis and Haemostasis on the 18th.

MG1113 is a hemophilia treatment made from antibodies that promote blood coagulation, unlike the conventional method of directly injecting the deficient coagulation factor into the blood. It is characterized by being usable regardless of the type of hemophilia or resistance to existing drugs.

The published paper explores the appropriate dosage of the drug that shows a stable in vivo response when administered to humans, based on the results of administration in animal models. In the animal model, the subcutaneous administration group of MG1113 showed higher bioavailability compared to the intravenous administration group. The results showed a long half-life maintaining prolonged drug efficacy.

Additionally, the research team confirmed that the therapeutic efficacy of the drug appeared in a dose-dependent manner.

They also applied efficacy parameters to the secured non-clinical trial results to calculate the clinical dose predicted to show efficacy in humans. GC Green Cross explained, "This study helped set the first patient dose for phase 1 clinical trials of MG1113."

The author of this paper, Eunyoung Kwak, head of the non-clinical team at GC Green Cross, said, "Using human simulation based on non-clinical trial results helped design a more accurate clinical trial," and added, "We hope MG1113, which has a long half-life and the convenience of subcutaneous injection, will become a new alternative to improve the quality of life for hemophilia patients."

This content was produced with the assistance of AI translation services.